Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
1998 1
1999 1
2000 17
2001 12
2002 14
2003 18
2004 14
2005 21
2006 11
2007 21
2008 23
2009 17
2010 17
2011 25
2012 38
2013 42
2014 44
2015 28
2016 28
2017 40
2018 39
2019 32
2020 56
2021 55
2022 48
2023 48
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Results by year

Filters applied: . Clear all
Page 1
Association of Inhaled Corticosteroids and Long-Acting beta-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis.
Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, Blake KV, Lang JE, Baker WL. Sobieraj DM, et al. JAMA. 2018 Apr 10;319(14):1485-1496. doi: 10.1001/jama.2018.2769. JAMA. 2018. PMID: 29554195 Free PMC article. Review.
IMPORTANCE: Combined use of inhaled corticosteroids and long-acting beta-agonists (LABAs) as the controller and the quick relief therapy termed single maintenance and reliever therapy (SMART) is a potential therapeutic regimen for the management of persistent asthma …
IMPORTANCE: Combined use of inhaled corticosteroids and long-acting beta-agonists (LABAs) as the controller and the quick reli …
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.
Crossingham I, Turner S, Ramakrishnan S, Fries A, Gowell M, Yasmin F, Richardson R, Webb P, O'Boyle E, Hinks TS. Crossingham I, et al. Cochrane Database Syst Rev. 2021 May 4;5(5):CD013518. doi: 10.1002/14651858.CD013518.pub2. Cochrane Database Syst Rev. 2021. PMID: 33945639 Free PMC article.
OBJECTIVES: To evaluate the efficacy and safety of single combined (fast-onset beta2-agonist plus an inhaled corticosteroid (ICS)) inhaler only used as needed in people with mild asthma. ...We included studies of a single fixed-dose FABA/ICS inhaler used as required compar …
OBJECTIVES: To evaluate the efficacy and safety of single combined (fast-onset beta2-agonist plus an inhaled corticosteroid (ICS)) in …
Croup.
Johnson DW. Johnson DW. BMJ Clin Evid. 2014 Sep 29;2014:0321. BMJ Clin Evid. 2014. PMID: 25263284 Free PMC article. Review.
Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications.
Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Agusti A, et al. Allergy. 2022 Apr;77(4):1105-1113. doi: 10.1111/all.15076. Epub 2021 Sep 15. Allergy. 2022. PMID: 34478578 Free PMC article. Review.
A significant number of patients with asthma remain uncontrolled despite treatment with inhaled corticosteroids (ICS) and long-acting beta2 adrenergic bronchodilators (LABA). The addition of long-acting antimuscarinic agents (LAMA) can improve the management of asthma in t …
A significant number of patients with asthma remain uncontrolled despite treatment with inhaled corticosteroids (ICS) and long-acting beta2 …
Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.
Cates CJ, Welsh EJ, Rowe BH. Cates CJ, et al. Cochrane Database Syst Rev. 2013 Sep 13;2013(9):CD000052. doi: 10.1002/14651858.CD000052.pub3. Cochrane Database Syst Rev. 2013. PMID: 24037768 Free PMC article. Review.
SELECTION CRITERIA: Randomised trials in adults and children (from two years of age) with asthma, where spacer beta(2)-agonist delivery was compared with wet nebulisation. DATA COLLECTION AND ANALYSIS: Two review authors independently applied study inclusion criteri …
SELECTION CRITERIA: Randomised trials in adults and children (from two years of age) with asthma, where spacer beta(2)-agonist …
Beta-adrenergic drugs and risk of Parkinson's disease: A systematic review and meta-analysis.
Singh A, Hussain S, Akkala S, Klugarová J, Pokorná A, Klugar M, Walters EH, Hopper I, Campbell JA, Taylor B, Antony B. Singh A, et al. Ageing Res Rev. 2022 Sep;80:101670. doi: 10.1016/j.arr.2022.101670. Epub 2022 Jun 17. Ageing Res Rev. 2022. PMID: 35718329 Review.
OBJECTIVES: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonists) drugs' use and PD. METHODS: An electronic literature search of eight databases was performed from inception to July 2021 to identify phar …
OBJECTIVES: This systematic review and meta-analyses evaluate the association between beta-adrenergic (agonists and antagonist …
Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd PN Jr. Kennelly MJ, et al. Adv Ther. 2021 Nov;38(11):5452-5464. doi: 10.1007/s12325-021-01902-8. Epub 2021 Sep 18. Adv Ther. 2021. PMID: 34537953 Free PMC article.
BACKGROUND: In the absence of head-to-head trials, we performed an indirect treatment comparison of the beta(3)-adrenergic agonists vibegron and mirabegron in the treatment of overactive bladder (OAB). ...
BACKGROUND: In the absence of head-to-head trials, we performed an indirect treatment comparison of the beta(3)-adrenergic ago …
Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.
Yang M, Li Y, Jiang Y, Guo S, He JQ, Sin DD. Yang M, et al. Eur Respir J. 2023 Feb 9;61(2):2200302. doi: 10.1183/13993003.00302-2022. Print 2023 Feb. Eur Respir J. 2023. PMID: 36137586
INTRODUCTION: Accumulated high-quality data from randomised controlled trials (RCTs) indicate that long-acting muscarinic antagonist (LAMA)/long-acting beta2 agonist (LABA) combination therapy significantly improves clinical symptoms and health status in patients with chro …
INTRODUCTION: Accumulated high-quality data from randomised controlled trials (RCTs) indicate that long-acting muscarinic antagonist (LAMA)/ …
662 results